VivoSeq
Gastroenterology

Short Bowel Syndrome

25

Pipeline Programs↗

10

Active Trials↗

18

Companies Involved↗

Short Bowel Syndrome is an emerging landscape with 25 programs across 18 companies. The most active players are 9 Meters Biopharma, Inc., GlyPharma Therapeutics, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 8 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

76/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

9

9 Meters Biopharma, Inc.

2 programs

Phase 2G

GlyPharma Therapeutics

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2N

Napo Pharmaceuticals, Inc.

1 program

Phase 2Zealand Pharma logo

Zealand Pharma

1 program

Phase 3M

Marathon Pharmaceuticals, LLC

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

69%

Small molecule

20 of 29 classified programs — the dominant modality here.

31%ALL OTHERSPeptide724%Protein / enzyme13%Vaccine13%

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

52

clinical trials

Completed28 · 54%
Recruiting7 · 13%
Terminated5 · 10%
Withdrawn4 · 8%
Unknown status4 · 8%
Enrolling by invitation2 · 4%
Other2 · 4%

Clinical Trials

Trial Activity

52 trials

TED_ORG: Study on Short Bowel Syndrome
Recruiting·MMeyer Children's Hospital IRCCS·N/A·NCT07400783·50 enrolled
Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
Recruiting·NNapo Therapeutics, S.p.A.·Phase 2·NCT06904872·18 enrolled
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
Recruiting·Takeda logoTakeda·N/A·NCT05023382·120 enrolled
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
Recruiting·CChongqing Peg-Bio Biopharm Co., Ltd.·Phase 3·NCT06512584·72 enrolled
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
Recruiting·LLindsey Russell, MD·Phase 1·NCT06326645·6 enrolled
A 90 Day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children With Short Bowel Syndrome Who Are Dependent on Parenteral Nutrition
Recruiting·BBoston Children's Hospital·Preclinical·NCT03530852·32 enrolled
An Open-label, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of 0.05 mg/kg/Day Subcutaneous Teduglutide Following Treatment of Short Bowel Syndrome for 24 Weeks in Chinese Adults Who Are Dependent on Parenteral Support
Recruiting·Takeda logoTakeda·Phase 3·NCT06973304·13 enrolled
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
Active, not recruiting·VVectivBio AG·Phase 3·NCT05018286·158 enrolled
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
Enrolling by invitation·Zealand Pharma logoZealand Pharma·Phase 3·NCT07228403·35 enrolled
A 90 Day Observational Study as an Extension to the Phase 3, Open Labeled, Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children With Short Bowel Syndrome Who Are Dependent on PN
Enrolling by invitation·BBoston Children's Hospital·N/A·NCT05635747·32 enrolled
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)
Completed·Takeda logoTakeda·Phase 3·NCT02954458·61 enrolled
Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
Completed·VVectivBio AG·Phase 2·NCT04964986·10 enrolled
Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT03562130·25 enrolled
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)
Completed·Takeda logoTakeda·Phase 3·NCT02340819·11 enrolled
Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome
Completed·—·Phase 1·NCT00767364·8 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)